Cagrilintide
Also known as CagriSema component, NN9838
Cagrilintide is a long-acting version of amylin, a hormone released with insulin that slows stomach emptying and signals fullness. Novo Nordisk is developing it in combination with semaglutide as CagriSema. It is an investigational medicine and not approved anywhere.
Who has Cagrilintide in stock
None of our live-checked suppliers has Cagrilintide in stock right now. Stock is re-checked every hour.
Live stock is checked hourly at 10 suppliers. A further 7 vetted suppliers have no live feed yet, so we never show them as in stock. We earn a commission from some supplier links when you buy. It costs you nothing extra and never changes the order, which is by price per mg.
What it has been studied for
- Weight loss in combination with semaglutide in the REDEFINE phase 3 trials
- Weight loss on its own in phase 2
- Blood sugar control in type 2 diabetes
Evidence level: Human trials. Human data exists, but read the details above before assuming it applies to you.
What happened in human trials
Tested alone and with semaglutide (CagriSema). Nausea, constipation and other stomach effects were the most common, as with the GLP-1 drugs.
Prohibited in drug-tested sport under the World Anti-Doping Code.
UK legal status
Not licensed in the UK. An investigational medicine available legitimately only inside clinical trials.
Handling
Supplied as a lyophilised powder. Reconstituted with bacteriostatic water and refrigerated once mixed. Commonly 5mg or 10mg per vial.
Questions
How much weight loss did CagriSema show?
In the REDEFINE 1 trial, people on the combination lost around 20% of body weight on average over 68 weeks, a little below what Novo Nordisk had projected.
Before you buy anything, run the four-question check for red flags that apply to you.